Related references
Note: Only part of the references are listed.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
Jan A. Burger et al.
BLOOD (2013)
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
Betty Y. Chang et al.
BLOOD (2013)
CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL
Mascha Binder et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
Robbert Hoogeboom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Jan A. Burger et al.
LEUKEMIA & LYMPHOMA (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Erica K. Evans et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice
Laurens P. Kil et al.
BLOOD (2012)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Colonel Bruton's Kinase Defined the Molecular Basis of X-Linked Agammaglobulinemia, the First Primary Immunodeficiency
Wasif N. Khan
JOURNAL OF IMMUNOLOGY (2012)
Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity
E. Kostareli et al.
LEUKEMIA (2012)
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Marcus Duehren-von Minden et al.
NATURE (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus
Jack Hutcheson et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk
Xingguang Liu et al.
NATURE IMMUNOLOGY (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
Betty Y. Chang et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Early Events in B Cell Activation
Naomi E. Harwood et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo
Sergey Krysov et al.
BLOOD (2010)
B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia
Hannah M. Kerns et al.
BLOOD (2010)
Update on gene therapy for immunodeficiencies
Donald B. Kohn
CLINICAL IMMUNOLOGY (2010)
Targeted covalent drugs of the kinase family
Juswinder Singh et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK
Y. Y. Ng et al.
LEUKEMIA (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Stereotypical Chronic Lymphocytic Leukemia B-Cell Receptors Recognize Survival Promoting Antigens on Stromal Cells
Mascha Binder et al.
PLOS ONE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Primary B Cell Immunodeficiencies: Comparisons and Contrasts
Mary Ellen Conley et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Tyrosine kinases and their substrates in B lymphocytes
Tomohiro Kurosaki et al.
IMMUNOLOGICAL REVIEWS (2009)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity
Tomohiro Kubo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
Anna Lanemo Myhrinder et al.
BLOOD (2008)
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA
Charles C. Chu et al.
BLOOD (2008)
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals
Masahiro Shinohara et al.
CELL (2008)
Bruton's Tyrosine Kinase as a Drug Discovery Target
Zhengying Pan
DRUG NEWS & PERSPECTIVES (2008)
Bruton's tyrosine kinase separately regulates NFκB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B cells
Koon-Guan Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Dual functions of Bruton's tyrosine kinase and tec kinase during Fcγ receptor-induced signaling and phagocytosis
Jenny Jongstra-Bilen et al.
JOURNAL OF IMMUNOLOGY (2008)
Essential roles for the Tec family kinases Tec and Btk in M-CSF receptor signaling pathways that regulate macrophage survival
Martin Melcher et al.
JOURNAL OF IMMUNOLOGY (2008)
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells
M. MacPartlin et al.
LEUKEMIA (2008)
Activation mechanism and steady state kinetics of Bruton's tyrosine kinase
Marie Dinh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Are Erk, Btk, and PECAM-1 major players in GPIb signaling? The challenge of unraveling signaling events downstream of platelet GPIb
Shaun P. Jackson et al.
BLOOD (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Bruton's tyrosine kinase and phospholipase C gamma 2 mediate chemokine-controlled B cell migration and homing
David J. J. de Gorter et al.
IMMUNITY (2007)
BDTKbase:: The mutation database for X-linked agammaglobullinemia
Jouni Valiaho et al.
HUMAN MUTATION (2006)
Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo
Junling Liu et al.
BLOOD (2006)
MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction
P Gray et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation
A Mansell et al.
NATURE IMMUNOLOGY (2006)
Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells
N Feldhahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFκB activation by lipopolysaccharide
SL Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells
N Feldhahn et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity
M Hervé et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity
S Middendorp et al.
BLOOD (2005)
Bruton's tyrosine kinase:: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling
JM Lindvall et al.
IMMUNOLOGICAL REVIEWS (2005)
Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia
FM Uckun et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Variability in the degree of expression of phosphorylated IκBα in chronic lymphocytic leukemia cases with nodal involvement
A Rodríguez et al.
CLINICAL CANCER RESEARCH (2004)
The B cell antigen receptor controls integrin activity through Btk and PLCγ2
M Spaargaren et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by toll-like receptor 4
CA Jefferies et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in pre-B cells
R Kersseboom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Phosphorylation of Bruton's tyrosine kinase by c-Abl
CM Bäckesjö et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development
TT Su et al.
JOURNAL OF IMMUNOLOGY (2002)
The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species
CIE Smith et al.
BIOESSAYS (2001)
Primary immunodeficiency diseases due to defects in lymphocytes.
RH Buckley
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement
JB Petro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation
UD Bajpai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
